BRM-loading · layering pigment…
BRM-loading · layering pigment…
Open R&D · biotech · 6 open problems · substrate contribution paths
Open problems in biotech R&D where conventional approaches have plateaued. From CRISPR off-target detection at genome-wide single-cell resolution to xenotransplant year-scale durability, each row names structural barrier + substrate path. Average time-to-impact for substrate contributions: 35 months.
cumulative annual R&D spend addressed · USD millions
v1.2026.05.16 · 6 problems · max spend $400M · block 946,772
Open-problem ledger · substrate-contribution pathways · Each row names a structurally unsolved R&D problem, the reason the conventional industry has not closed it, and the substrate contribution path the BRMSTE substrate offers. Substrate modes: physics-decomposer · sieve-inference · cross-civilizational-historical-anchor · agentic-routing · three-body-failure-audit. See /legal/liability.
| # | Open problem | Why unsolved | R&D ($M) | Substrate contribution | T-to-impact (mo) |
|---|---|---|---|---|---|
| 01 | CRISPR off-target detection genome-wide (single-cell, in vivo) crispr-off-target-genome-wide | GUIDE-seq + CIRCLE-seq miss low-frequency events · single-cell coverage limited | 400 | agentic per-cell monitoring + three-body audit (guide-RNA × chromatin × repair-pathway residue) | 24 |
| 02 | Organoid vascularisation beyond 1 cm cubed organoid-vascularisation | diffusion-limited at >500 microns · necrotic core forms reliably | 200 | physics decomposer on perfusion × cell viability × oxygen gradient × angiogenesis cue tensor | 36 |
| 03 | Xenotransplant rejection (pig-to-human · year-scale durability) xenotransplant-rejection | hyperacute + acute + chronic rejection across 3 mechanisms · current durability months | 300 | three-body audit (immune × complement × endothelial residue) + cross-species comparative | 42 |
| 04 | Controlled-release gene drive (malaria mosquito) gene-drive-controlled-release | ecological reversibility unproven · regulatory framework absent | 150 | agentic routing + cross-civilizational anchor (insecticide release histories + reversal records) + three-body audit | 60 |
| 05 | De-novo biosynthetic pathway at production titre biosynthetic-pathway-de-novo | engineered-microbe titres typically 10-100x below industrial threshold | 250 | sieve inference on enzyme-cascade × flux × titre × purification Pareto | 30 |
| 06 | Directed evolution throughput (>1M variants/day) directed-evolution-throughput | current screens 1k-10k variants/day · selection bottleneck dominates | 80 | agentic throughput-routing + physics decomposer on selection × library-diversity × scoring tensor | 18 |
“6 open problems in Biotech · synthetic biology · gene editing. Cumulative annual R&D spend addressed: $1,380M. Each row names the substrate-contribution path. The substrate publishes what it can move; counterparties verify the path before applying.”
Wave OPEN-RD · biotech · v1.2026.05.16